Stroke neuroprotection: Targeting mitochondria

Brain Sciences

Volumn 3, Issue 2, 2013, Pages 540-560

  Watts, Lora Talley ^a   Lloyd, Reginald ^a   Garling, Richard Justin ^a   Duong, Timothy ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Methylene blue; Mitochondria; Neuroprotection; Purinergic receptor; Stroke; Superoxide dismutase

Indexed keywords

2 METHYLTHIOADENOSINE DIPHOSPHATE TRISODIUM SALT; ADENOSINE TRIPHOSPHATE; ALTEPLASE; ANTIMYCIN A1; GLUTATHIONE; IMISOPASEM MANGANESE; METHYLENE BLUE; OLIGOMYCIN; PHOSPHOLIPASE C; PROTEIN KINASE C; PURINERGIC P2X RECEPTOR; PURINERGIC P2X2 RECEPTOR; PURINERGIC P2X4 RECEPTOR; PURINERGIC P2X6 RECEPTOR; PURINERGIC P2Y RECEPTOR; PURINERGIC RECEPTOR; PURINERGIC RECEPTOR STIMULATING AGENT; REACTIVE OXYGEN METABOLITE; ROTENONE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; APOPTOSIS; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR ACCIDENT; EDEMA; HUMAN; LOW DRUG DOSE; MITOCHONDRION; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; REVIEW; STIMULATION;

EID: 84929572141     PISSN: None     EISSN: 20763425     Source Type: Journal    
DOI: 10.3390/brainsci3020540     Document Type: Review

References (131)

1. Roger, V.L.; Go, A.S.; Lloyd-Jones, D.M.; Adams, R.J.; Berry, J.D.; Brown, T.M.; Carnethon, M.R.; Dai, S.; de Simone, G.; Ford, E.S.; et al. Heart disease and stroke statistics-2011 update: A report from the American Heart Association. Circulation 2011, 123, e18-e209.
2. Shang, W.; Liu, J. Stroke subtype classification: A comparative study of ASCO and modified TOAST. J. Neurol. Sci. 2012, 314, 66-70.
3. Abbott, N.J.; Ronnback, L.; Hansson, E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 2006, 7, 41-53.
4. Globus, M.Y.; Busto, R.; Lin, B.; Schnippering, H.; Ginsberg, M.D. Detection of free radical activity during transient global ischemia and recirculation: Effects of intraischemic brain temperature modulation. J. Neurochem. 1995, 65, 1250-1256.
5. Sherman, D.G.; Easton, J.D. Cerebral edema in stroke: A common, often fatal complication. Postgrad. Med. 1980, 68, 107-113, 116, 119-120.
6. Brouns, R.; Wauters, A.; de Surgeloose, D.; Marien, P.; de Deyn, P.P. Biochemical markers for blood-brain barrier dysfunction in acute ischemic stroke correlate with evolution and outcome. Eur. Neurol. 2011, 65, 23-31.
7. Hakim, A. The cerebral ischemic penumbra. Can. J. Neurol. Sci. 1987, 14, 557-559.
8. Schlaug, G.; Benfield, A.; Baird, A.; Siewert, B.; Lövblad, K.; Parker, R.; Edelman, R.; Warach, S. The ischemic penumbra. Neurology 1999, 53, 1528-1528.
9. Guadagno, J.V.; Donnan, G.A.; Markus, R.; Gillard, J.H.; Baron, J.C. Imaging the ischaemic penumbra. Curr. Opin. Neurol. 2004, 17, 61-67.
10. Soares, B.P.; Chien, J.D.; Wintermark, M. MR and CT Monitoring of Recanalization, Reperfusion, and Penumbra Salvage. Stroke 2009, 40, S24-S27.
11. Ferrer, I.; Planas, A.M. Signaling of cell death and cell survival following focal cerebral ischemia: Life and death struggle in the penumbra. J. Neuropathol. Exp. Neurol. 2003, 62, 329-339.
12. Wass, C.T.; Lanier, W.L. Glucose modulation of ischemic brain injury: Review and clinical recommendations. Mayo Clin. Proc. 1996, 71, 801-812.
13. Bruno, A.; Biller, J.; Adams, H.P., Jr.; Clarke, W.R.; Woolson, R.F.; Williams, L.S.; Hansen, M.D. Acute blood glucose level and outcome from ischemic stroke. Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Neurology 1999, 52, 280-284.
14. Reith, J.; Jorgensen, H.S.; Pedersen, P.M.; Nakayama, H.; Raaschou, H.O.; Jeppesen, L.L.; Olsen, T.S. Body temperature in acute stroke: Relation to stroke severity, infarct size, mortality, and outcome. Lancet 1996, 347, 422-425.
15. Garcia, J.H.; Lassen, N.A.; Weiller, C.; Sperling, B.; Nakagawara, J. Ischemic stroke and incomplete infarction. Stroke 1996, 27, 761-765.
16. Del Zoppo, G.J.; Pessin, M.S.; Mori, E.; Hacke, W. Thrombolytic intervention in acute thrombotic and embolic stroke. Semin. Neurol. 1991, 11, 368-384.
17. Siesjo, B.K. Cell damage in the brain: A speculative synthesis. J. Cereb. Blood Flow Metab. 1981, 1, 155-185.
18. Siesjo, B.K.; Agardh, C.D.; Bengtsson, F. Free radicals and brain damage. Cerebrovasc. Brain Metab. Rev. 1989, 1, 165-211.
19. Rothman, S.M.; Olney, J.W. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann. Neurol. 1986, 19, 105-111.
20. Becker, K.J. Inflammation and acute stroke. Curr. Opin. Neurol. 1998, 11, 45-49.
21. Hademenos, G.J.; Massoud, T.F. Biophysical mechanisms of stroke. Stroke 1997, 28, 2067-2077.
22. DeGraba, T.J. The role of inflammation after acute stroke: Utility of pursuing anti-adhesion molecule therapy. Neurology 1998, 51, S62-S68.
23. Kroemer, G.; Petit, P.; Zamzami, N.; Vayssiere, J.L.; Mignotte, B. The biochemistry of programmed cell death. FASEB J. 1995, 9, 1277-1287.
24. Garcia, J.H.; Liu, K.-F.; Ho, K.-L. Neuronal necrosis after middle cerebral artery occlusion in Wistar rats progresses at different time intervals in the audoputamen and the cortex. Stroke 1995, 26, 636-643.
25. Davis, S.M.; Donnan, G.A. 4.5 hours: The new time window for tissue plasminogen activator in stroke. Stroke 2009, 40, 2266-2267.
26. Kleindorfer, D.; Kissela, B.; Schneider, A.; Woo, D.; Khoury, J.; Miller, R.; Alwell, K.; Gebel, J.; Szaflarski, J.; Pancioli, A.; et al. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: A population-based study. Stroke 2004, 35, e27-e29.
27. Crumrine, R.C.; Marder, V.J.; Taylor, G.M.; Lamanna, J.C.; Tsipis, C.P.; Scuderi, P.; Petteway, S.R., Jr.; Arora, V. Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model. Exp. Transl. Stroke Med. 2011, 3, 10.
28. Hacke, W.; Donnan, G.; Fieschi, C.; Kaste, M.; von Kummer, R.; Broderick, J.P.; Brott, T.; Frankel, M.; Grotta, J.C.; Haley, E.C., Jr.; et al. Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004, 363, 768-774.
29. Wahlgren, N.; Ahmed, N.; Davalos, A.; Ford, G.A.; Grond, M.; Hacke, W.; Hennerici, M.G.; Kaste, M.; Kuelkens, S.; Larrue, V.; et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): An observational study. Lancet 2007, 369, 275-282.
30. Suzuki, S.; Saver, J.L.; Scott, P.; Jahan, R.; Duckwiler, G.; Starkman, S.; Su, Y.; Kidwell, C.S. Access to intra-arterial therapies for acute ischemic stroke: An analysis of the US population. AJNR Am. J. Neuroradiol. 2004, 25, 1802-1806.
31. Chih, C.P.; Roberts, E.L. Energy substrates for neurons during neural activity: A critical review of the astrocyte-neuron lactate shuttle hypothesis. J. Cereb. Blood Flow Metab. 2003, 23, 1263-1281.
32. Swanson, R.A.; Benington, J. Astrocyte glucose metabolism under normal and pathological conditions in vitro. Dev. Neurosci. 1996, 18, 515-521.
33. Swanson, R.A.; Yu, A.C.H.; Sharp, F.R.; Chan, P.H. Regulation of glycogen content in primary astrocyte culture: Effects of glucose analogues, phenobarbital, and methionine sulfoximine. J. Neurochem. 1989, 52, 1359-1365.
34. Detmer, S.A.; Chan, D.C. Functions and dysfunctions of mitochondrial dynamics. Nat. Rev. Mol. Cell Biol. 2007, 8, 870-879.
35. Sies, H. Oxidative stress: From basic research to clinical application. Am. J. Med. 1991, 91, 31S-38S.
36. Balaban, R.S.; Nemoto, S.; Finkel, T. Mitochondria, oxidants, and aging. Cell 2005, 120, 483-495.
37. + leak and ROS generation: An odd couple. Free Radic. Biol. Med. 2005, 38, 12-23.
38. Nohl, H.; Gille, L.; Staniek, K. Intracellular generation of reactive oxygen species by mitochondria. Biochem. Pharmacol. 2005, 69, 719-723.
39. Raha, S.; Robinson, B.H. Mitochondria, oxygen free radicals, disease and ageing. Trends Biochem. Sci. 2000, 25, 502-508.
40. Raha, S.; Robinson, B.H. Mitochondria, oxygen free radicals, and apoptosis. Am. J. Med. Genet. 2001, 106, 62-70.
41. Pastorino, J.G.; Snyder, J.W.; Serroni, A.; Hoek, J.B.; Farber, J.L. Cyclosporin and carnitine prevent the anoxic death of cultured hepatocytes by inhibiting the mitochondrial permeability transition. J. Biol. Chem. 1993, 268, 13791-13798.
42. Zahrebelski, G.; Nieminen, A.L.; Al-Ghoul, K.; Qian, T.; Herman, B.; Lemasters, J.J. Progression of subcellular changes during chemical hypoxia to cultured rat hepatocytes: A laser scanning confocal microscopic study. Hepatology 1995, 21, 1361-1372.
43. Beal, M.F.; Brouillet, E.; Jenkins, B.G.; Ferrante, R.J.; Kowall, N.W.; Miller, J.M.; Storey, E.; Srivastava, R.; Rosen, B.R.; Hyman, B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 1993, 13, 4181-4192.
44. Dawson, T.L.; Gores, G.J.; Nieminen, A.L.; Herman, B.; Lemasters, J.J. Mitochondria as a source of reactive oxygen species during reductive stress in rat hepatocytes. Am. J. Physiol. 1993, 264, C961-C967.
45. Newmeyer, D.D.; Farschon, D.M.; Reed, J.C. Cell-free apoptosis in Xenopus egg extracts: Inhibition by Bcl-2 and requirement for an organelle fraction enriched in mitochondria. Cell 1994, 79, 353-364.
46. Zamzami, N.; Susin, S.A.; Marchetti, P.; Hirsch, T.; Gomez-Monterrey, I.; Castedo, M.; Kroemer, G. Mitochondrial control of nuclear apoptosis. J. Exp. Med. 1996, 183, 1533-1544.
47. Petit, P.X.; Lecoeur, H.; Zorn, E.; Dauguet, C.; Mignotte, B.; Gougeon, M.L. Alterations in mitochondrial structure and function are early events of dexamethasone-induced thymocyte apoptosis. J. Cell Biol. 1995, 130, 157-167.
48. Kroemer, G. Mitochondrial implication in apoptosis. Towards an endosymbiont hypothesis of apoptosis evolution. Cell Death Differ. 1997, 4, 443-456.
49. Chan, K.; Han, X.D.; Kan, Y.W. An important function of Nrf2 in combating oxidative stress: Detoxification of acetaminophen. Proc. Natl. Acad. Sci. USA 2001, 98, 4611-4616.
50. Sawada, M.; Sester, U.; Carlson, J.C. Superoxide radical formation and associated biochemical alterations in the plasma membrane of brain, heart, and liver during the lifetime of the rat. J. Cell. Biochem. 1992, 48, 296-304.
51. Antier, D.; Carswell, H.V.; Brosnan, M.J.; Hamilton, C.A.; Macrae, I.M.; Groves, S.; Jardine, E.; Reid, J.L.; Dominiczak, A.E. Increased levels of superoxide in brains from old female rats. Free Radic. Res. 2004, 38, 177-183.
52. Dienel, G.A.; Hertz, L. Astrocytic contributions to bioenergetics of cerebral ischemia. Glia 2005, 50, 362-388.
53. Bernardi, M.L.; Flechon, J.E.; Delouis, C. Influence of culture system and oxygen tension on the development of ovine zygotes matured and fertilized in vitro. J. Reprod. Fertil. 1996, 106, 161-167.
54. Bains, J.S.; Shaw, C.A. Neurodegenerative disorders in humans: The role of glutathione in oxidative stress-mediated neuronal death. Brain Res. Brain Res. Rev. 1997, 25, 335-358.
55. Robb, S.J.; Connor, J.R. An in vitro model for analysis of oxidative death in primary mouse astrocytes. Brain Res. 1998, 788, 125-132.
56. Amin, N.; Pearce, B. Glutamate toxicity in neuron-enriched and neuron-astrocyte co-cultures: Effect of the glutamate uptake inhibitor L-trans-pyrrolidine-2,4-dicarboxylate. Neurochem. Int. 1997, 30, 271-276.
57. Winn, H.R.; Rubio, R.; Berne, R.M. Brain adenosine production in the rat during 60 seconds of ischemia. Circ. Res. 1979, 45, 486-492.
58. Schultz, S.G. Pump-leak parallelism in sodium-absorbing epithelia: The role of ATP-regulated potassium channels. J. Exp. Zool. 1997, 279, 476-483.
59. Liu, S.; Levine, S.R.; Winn, H.R. Targeting ischemic penumbra: Part I-from pathophysiology to therapeutic strategy. J. Exp. Stroke Transl. Med. 2010, 3, 47-55.
60. Abbracchio, M.P.; Burnstock, G. Purinergic signalling: Pathophysiological roles. Jpn. J. Pharmacol. 1998, 78, 113-145.
61. Fredholm, B.B. Purinoceptors in the nervous system. Pharmacol. Toxicol. 1995, 76, 228-239.
62. Kowaluk, E.A.; Bhagwat, S.S.; Jarvis, M.F. Adenosine kinase inhibitors. Curr. Pharm. Des. 1998, 4, 403-416.
63. Rudolphi, K.A.; Schubert, P.; Parkinson, F.E.; Fredholm, B.B. Neuroprotective role of adenosine in cerebral ischaemia. Trends Pharmacol. Sci. 1992, 13, 439-445.
64. Williams, M.; Burnstock, G. Purinergic Neurotransmission and Neuromodulation: A Historical Perspective; Wiley-Liss: New York, NY, USA, 1997.
65. Winn, H.R.; Rubio, G.R.; Berne, R.M. The role of adenosine in the regulation of cerebral blood flow. J. Cereb. Blood Flow Metab. 1981, 1, 239-244.
66. Zhou, G.; Smith, J.L.; Zalkin, H. Binding of purine nucleotides to two regulatory sites results in synergistic feedback inhibition of glutamine 5-phosphoribosylpyrophosphate amidotransferase. J. Biol. Chem. 1994, 269, 6784-6789.
67. Ralevic, V.; Burnstock, G. Receptors for purines and pyrimidines. Pharmacol. Rev. 1998, 50, 413-492.
68. Verkhratsky, A.; Kettenmann, H. Calcium signalling in glial cells. Trends Neurosci. 1996, 19, 346-352.
69. 2+ signalling in glial cell pathology in the central nervous system. Eur. J. Pharmacol. 2002, 447, 247-260.
70. 2+ transport by mitochondria. Nature 1985, 315, 635.
71. McCormack, J.G.; Halestrap, A.P.; Denton, R.M. Role of calcium ions in regulation of mammalian intramitochondrial metabolism. Physiol. Rev. 1990, 70, 391-425.
72. Hajnoczky, G.; Csordas, G.; Krishnamurthy, R.; Szalai, G. Mitochondrial calcium signaling driven by the IP3 receptor. J. Bioenerg. Biomembr. 2000, 32, 15-25.
73. Hajnoczky, G.; Robb-Gaspers, L.D.; Seitz, M.B.; Thomas, A.P. Decoding of cytosolic calcium oscillations in the mitochondria. Cell 1995, 82, 415-424.
74. Sak, K.; Webb, T.E. A retrospective of recombinant P2Y receptor subtypes and their pharmacology. Arch. Biochem. Biophys. 2002, 397, 131-136.
75. Burnstock, G. P2X receptors in sensory neurones. Br. J. Anaesth. 2000, 84, 476-488.
76. Burnstock, G. Physiology and pathophysiology of purinergic neurotransmission. Physiol. Rev. 2007, 87, 659-797.
77. Fabre, J.E.; Nguyen, M.; Latour, A.; Keifer, J.A.; Audoly, L.P.; Coffman, T.M.; Koller, B.H. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat. Med. 1999, 5, 1199-1202.
78. Leon, C.; Hechler, B.; Freund, M.; Eckly, A.; Vial, C.; Ohlmann, P.; Dierich, A.; LeMeur, M.; Cazenave, J.P.; Gachet, C. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y1 receptor-null mice. J. Clin. Invest. 1999, 104, 1731-1737.
79. Wu, O.; Sumii, T.; Asahi, M.; Sasamata, M.; Ostergaard, L.; Rosen, B.R.; Lo, E.H.; Dijkhuizen, R.M. Infarct prediction and treatment assessment with MRI-based algorithms in experimental stroke models. J. Cereb. Blood Flow Metab. 2007, 27, 196-204.
80. Zheng, W.; Watts, L.T.; Holstein, D.M.; Prajapati, S.I.; Keller, C.; Grass, E.H.; Walter, C.A.; Lechleiter, J.D. Purinergic receptor stimulation reduces cytotoxic edema and brain infarcts in mouse induced by photothrombosis by energizing glial mitochondria. PLos One 2010, 5, e14401.
81. Zheng, W.; Talley Watts, L.; Holstein, D.M.; Wewer, J.; Lechleiter, J.D. P2Y1R-initiated, IP3R-dependent stimulation of astrocyte mitochondrial metabolism reduces and partially reverses ischemic neuronal damage in mouse. J. Cereb. Blood Flow Metab. 2012, 33, 600-611.
82. Owens, A.P., III; Mackman, N. Tissue factor and thrombosis: The clot starts here. Thromb. Haemost. 2010, 104, 432-439.
83. 2+ release enhances neuroprotection by increasing astrocyte mitochondrial metabolism during aging. J. Neurosci. 2007, 27, 6510-6520.
84. Savi, P.; Beauverger, P.; Labouret, C.; Delfaud, M.; Salel, V.; Kaghad, M.; Herbert, J.M. Role of P2Y1 purinoceptor in ADP-induced platelet activation. FEBS Lett. 1998, 422, 291-295.
85. Jin, J.; Daniel, J.L.; Kunapuli, S.P. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J. Biol. Chem. 1998, 273, 2030-2034.
86. Jin, J.; Kunapuli, S.P. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc. Natl. Acad. Sci. USA 1998, 95, 8070-8074.
87. Hechler, B.; Leon, C.; Vial, C.; Vigne, P.; Frelin, C.; Cazenave, J.P.; Gachet, C. The P2Y1 receptor is necessary for adenosine 5'-diphosphate-induced platelet aggregation. Blood 1998, 92, 152-159.
88. Jarvis, G.E.; Humphries, R.G.; Robertson, M.J.; Leff, P. ADP can induce aggregation of human platelets via both P2Y1 and P2T receptors. Br. J. Pharmacol. 2000, 129, 275-282.
89. Chhatriwala, M.; Ravi, R.G.; Patel, R.I.; Boyer, J.L.; Jacobson, K.A.; Harden, T.K. Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog. J. Pharmacol. Exp. Ther. 2004, 311, 1038-1043.
90. Ravi, R.G.; Kim, H.S.; Servos, J.; Zimmermann, H.; Lee, K.; Maddileti, S.; Boyer, J.L.; Harden, T.K.; Jacobson, K.A. Adenine nucleotide analogues locked in a Northern methanocarba conformation: Enhanced stability and potency as P2Y(1) receptor agonists. J. Med. Chem. 2002, 45, 2090-2100.
91. Lu, M.; Zhang, R.L.; Zhang, Z.G.; Yang, J.J.; Chopp, M. Linkage of cell cycle kinetics between embryonic and adult stroke models: An analytical approach. J. Neurosci. Methods 2007, 161, 323-330.
92. Cavaliere, F.; Florenzano, F.; Amadio, S.; Fusco, F.R.; Viscomi, M.T.; D'Ambrosi, N.; Vacca, F.; Sancesario, G.; Bernardi, G.; Molinari, M.; Volonte, C. Up-regulation of P2X2, P2X4 receptor and ischemic cell death: prevention by P2 antagonists. Neuroscience 2003, 120, 85-98.
93. Rojas, J.C.; Bruchey, A.K.; Gonzalez-Lima, F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog. Neurobiol. 2012, 96, 32-45.
94. Guttmann, P.; Ehrlich, P. Über die Wirkung des Methylenblau bei Malaria. Berl. Klin. Wochenschr. 1891, 28, 953-956.
95. Kupfer, A.; Aeschlimann, C.; Cerny, T. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur. J. Clin. Pharmacol. 1996, 50, 249-252.
96. Wainwright, M.; Crossley, K.B. Methylene Blue-A therapeutic dye for all seasons? J. Chemother. 2002, 14, 431-443.
97. Naylor, G.J.; Martin, B.; Hopwood, S.E.; Watson, Y. A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis. Biol. Psychiatry 1986, 21, 915-920.
98. Zhang, X.; Rojas, J.C.; Gonzalez-Lima, F. Methylene blue prevents neurodegeneration caused by rotenone in the retina. Neurotox. Res. 2006, 9, 47-57.
99. Peter, C.; Hongwan, D.; Kupfer, A.; Lauterburg, B.H. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur. J. Clin. Pharmacol. 2000, 56, 247-250.
100. Oz, M.; Lorke, D.E.; Petroianu, G.A. Methylene blue and Alzheimer's disease. Biochem. Pharmacol. 2009, 78, 927-932.
101. Wiklund, L.; Basu, S.; Miclescu, A.; Wiklund, P.; Ronquist, G.; Sharma, H.S. Neuro-and cardioprotective effects of blockade of nitric oxide action by administration of methylene blue. Ann. N. Y. Acad. Sci. 2007, 1122, 231-244.
102. Miclescu, A.; Basu, S.; Wiklund, L. Cardio-cerebral and metabolic effects of methylene blue in hypertonic sodium lactate during experimental cardiopulmonary resuscitation. Resuscitation 2007, 75, 88-97.
103. Kelner, M.J.; Bagnell, R.; Hale, B.; Alexander, N.M. Potential of methylene blue to block oxygen radical generation in reperfusion injury. Basic Life Sci. 1988, 49, 895-898.
104. Miclescu, A.; Basu, S.; Wiklund, L. Methylene blue added to a hypertonic-hyperoncotic solution increases short-term survival in experimental cardiac arrest. Crit. Care Med. 2006, 34, 2806-2813.
105. Wen, Y.; Li, W.; Poteet, E.C.; Xie, L.; Tan, C.; Yan, L.J.; Ju, X.; Liu, R.; Qian, H.; Marvin, M.A.; et al. Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. J. Biol. Chem. 2011, 286, 16504-16515.
106. Lin, A.L.; Poteet, E.; Du, F.; Gourav, R.C.; Liu, R.; Wen, Y.; Bresnen, A.; Huang, S.; Fox, P.T.; Yang, S.H.; Duong, T.Q. Methylene blue as a cerebral metabolic and hemodynamic enhancer. Plos One 2012, 7, e46585.
107. Huang, S.; Du, F.; Shih, Y.I.; Shen Q.; Gonzalez-Lima, F.; Duong, T.Q. Methylene blue potentiates stimulus-evoked fMRI responses and cerebral oxygen consumption during normoxia and hypoxia. NeuroImage 2013, 72, 237-242.
108. Devasagayam, T.P.; Tilak, J.C.; Boloor, K.K.; Sane, K.S.; Ghaskadbi, S.S.; Lele, R.D. Free radicals and antioxidants in human health: Current status and future prospects. J. Assoc. Physicians India 2004, 52, 794-804.
109. Holley, A.K.; Bakthavatchalu, V.; Velez-Roman, J.M.; St Clair, D.K. Manganese superoxide dismutase: Guardian of the powerhouse. Int. J. Mol. Sci. 2011, 12, 7114-7162.
110. Niizuma, K.; Endo, H.; Chan, P.H. Oxidative stress and mitochondrial dysfunction as determinants of ischemic neuronal death and survival. J. Neurochem. 2009, 109 (Suppl. 1), 133-138.
111. Holley, A.K.; Dhar, S.K.; St Clair, D.K. Manganese superoxide dismutase vs. p53: Regulation of mitochondrial ROS. Mitochondrion 2010, 10, 649-661.
112. Shmonin, A.; Melnikova, E.; Galagudza, M.; Vlasov, T. Characteristics of cerebral ischemia in major rat stroke models of middle cerebral artery ligation through craniectomy. Int. J. Stroke 2012, doi:10.1111/j.1747-4949.2012.00947.x.
113. Maier, C.M.; Hsieh, L.; Crandall, T.; Narasimhan, P.; Chan, P.H. A new approach for the investigation of reperfusion-related brain injury. Biochem. Soc. Trans. 2006, 34, 1366-1369.
114. Ivanovi-Burmazovi C, I.; Filipovi C, M. Reactivity of manganese superoxide dismutase mimics toward superoxide and nitric oxide: Selectivity versus cross-reactivity. Adv. Inorg. Chem. 2012, 64, 53-95.
115. Friedel, F.C.; Lieb, D.; Ivanovic-Burmazovic, I. Comparative studies on manganese-based SOD mimetics, including the phosphate effect, by using global spectral analysis. J. Inorg. Biochem. 2012, 109, 26-32.
116. Park, W.; Lim, D. Synthesis and SOD activity of manganese complexes of pentaaza macrocycles containing amino-and guanidino-auxiliary. Bull. Korean Chem. Soc. 2001, 32, 3787.
117. Huang, H.F.; Guo, F.; Cao, Y.Z.; Shi, W.; Xia, Q. Neuroprotection by manganese superoxide dismutase (MnSOD) mimics: Antioxidant effect and oxidative stress regulation in acute experimental stroke. CNS Neurosci. Ther. 2012, 18, 811-818.
118. Kelso, G.F.; Maroz, A.; Cocheme, H.M.; Logan, A.; Prime, T.A.; Peskin, A.V.; Winterbourn C.C.; James, A.M.; Ross, M.F.; Brooker, S.; et al. A Mitochondria-Targeted Macrocyclic Mn(II) Superoxide Dismutase Mimetic. Chem. Biol. 2012, 19, 1237-1246.
119. Shen, Q.; Fisher, M.; Sotak, C.H.; Duong, T.Q. Effects of reperfusion on ADC and CBF pixel-by-pixel dynamics in stroke: Characterizing tissue fates using quantitative diffusion and perfusion imaging. J. Cereb. Blood Flow Metab. 2004, 24, 280-290.
120. Shen, Q.; Huang, S.; Du, F.; Duong, T.Q. Probing ischemic tissue fate with bold fMRI of brief oxygen challenge. Brain Res. 2011, 1425, 132-141.
121. Shen, Q.; Meng, X.; Fisher, M.; Sotak, C.H.; Duong, T.Q. Pixel-by-pixel spatiotemporal progression of focal ischemia derived using quantitative perfusion and diffusion imaging. J. Cereb. Blood Flow Metab. 2003, 23, 1479-1488.
122. Shen, Q.; Ren, H.; Cheng, H.; Fisher, M.; Duong, T.Q. Functional, perfusion and diffusion MRI of acute focal ischemic brain injury. J. Cereb. Blood Flow Metab. 2005, 25, 1265-1279.
123. Meng, X.; Fisher, M.; Shen, Q.; Sotak, C.H.; Duong, T.Q. Characterizing the diffusion/perfusion mismatch in experimental focal cerebral ischemia. Ann. Neurol. 2004, 55, 207-212.
124. Hui, E.S.; Du, F.; Huang, S.; Shen, Q.; Duong, T.Q. Spatiotemporal dynamics of diffusional kurtosis, mean diffusivity and perfusion changes in experimental stroke. Brain Res. 2012, 1451, 100-109.
125. Sicard, K.M.; Henninger, N.; Fisher, M.; Duong, T.Q.; Ferris, C.F. Long-term changes of functional MRI based brain function, behavioral status, and histopathology after transient focal cerebral ischemia in rats. Stroke 2006, 37, 2593-2600.
126. Sicard, K.M.; Henninger, N.; Fisher, M.; Duong, T.Q.; Ferris, C.F. Differential recovery of multimodal mri and behavior after transient focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab. 2006, 26, 1451-1462.
127. Tanaka, Y.; Ishii, H.; Hiraoka, M.; Miyasaka, N.; Kuroiwa, T.; Hajjar K.A.; Nagaoka, T.; Duong, T.Q.; Ohno, K.; Yoshida, M. Efficacy of recombinant annexin 2 for fibrinolytic therapy in a rat embolic stroke model: A magnetic resonance imaging study. Brain Res. 2007, 1165, 135-143.
128. Shen, Q.; Ren, H.; Fisher, M.; Bouley, J.; Duong, T.Q. Dynamic tracking of acute ischemic tissue fates using improved unsupervised isodata analysis of high-resolution quantitative perfusion and diffusion data. J. Cereb. Blood Flow Metab. 2004, 24, 887-897.
129. Shen, Q.; Ren, H.; Fisher, M.; Duong, T.Q. Statistical prediction of tissue fate in acute ischemic brain injury. J. Cereb. Blood Flow Metab. 2005, 25, 1336-1345.
130. Huang, S.; Shen, Q.; Duong, T.Q. Artificial neural network prediction of ischemic tissue fate in acute stroke imaging. J. Cereb. Blood Flow Metab. 2010, 30, 1661-1670.
131. Huang, S.; Shen, Q.; Duong, T.Q. Quantitative prediction of acute ischemic tissue fate using support vector machine. Brain Res. 2011, 1405, 77-84.